|
AlgoNomics and Pepscan Systems announce positive results with their Peptide-Design-Cycle platform
Ghent, Belgium and Lelystad, The Netherlands, September 12 2003 - Belgium
based AlgoNomics and The Netherlands based Pepscan Systems announce positive results in the rational design of antibody binding peptides. The companies announce their intention to exploit their “peptide-design-cycle” platform in the vaccination field.
AlgoNomics’ Tripole® technology combines extensive protein modelling know-how
with the latest peptide design techniques to explore the interaction between peptides
and proteins.
Pepscan Systems’ peptide array platform offers the ideal assay-system for studying
protein-protein interactions as well as protein-peptide interaction, including
identification of novel peptides and their interaction with antibodies.
By combining structural bioinformatics and in vitro peptide analysis, the companies
unveiled peptide sequence motifs that bind to specific antibodies.
These results, supported by a governemental research grant of the IWT (BE), form a
solid basis for follow-on projects in the cancer vaccination field.
In a reaction AlgoNomics’ CEO, Dr. Ignace Lasters, said: “These results show that it
is possible to identify peptides that bind strongly to a receptor using an iterative
design cycle combining AlgoNomics’ structural bioinformatics platform and Pepscan
Systems’ expert know-how in peptide analysis.”
“We are extremely happy that the combined technologies of AlgoNomics and
Pepscan leads to the identification of very useful, novel peptide motifs”, comments
Rob Meloen, CSO of Pepscan Systems.
AlgoNomics and Pepscan Systems express the intention to further exploit their knowhow
in a joint cancer vaccine initiative.
AlgoNomics N.V. is a Belgium-based vaccine development company with a strong
focus on structural bioinformatics. AlgoNomics’ Tripole® platform is to be applied on
peptide and antibody leads. AlgoNomics’ Epibase® platform is focused on the
design on efficient vaccines.
Pepscan Systems BV is a Dutch biotech company offering peptide-based discovery
technologies for studying protein-protein interactions and identification of lead
peptides. These tools are internally used for a strong pipeline of synthetic peptide
vaccines that target humoral mediators of oncology.
Contact
|
